BioMedicine
Volume 12

Issue 4

Article 6

2022

The expression of ACAT1 in oral squamous cell carcinoma and
the adjacent pre-tumour tissue

Follow this and additional works at: https://www.biomedicinej.com/biomedicine
Part of the Life Sciences Commons, and the Medical Sciences Commons

This work is licensed under a Creative Commons Attribution 4.0 License.
Recommended Citation
Firouzpour, Hadis; Shokrolahi, Seyed Mohammad; Bourova-Flin, Ekaterina; Derakhshan, Samira;
Shahsavari, Zahra; Karimi, Abbas; Mir Mohammad Sadeghi, Hassan; and Goudarzi, Afsaneh (2022) "The
expression of ACAT1 in oral squamous cell carcinoma and the adjacent pre-tumour tissue," BioMedicine:
Vol. 12 : Iss. 4 , Article 6.
DOI: 10.37796/2211-8039.1363

This Original Articles is brought to you for free and open access by BioMedicine. It has been accepted for inclusion
in BioMedicine by an authorized editor of BioMedicine.

Hadis Firouzpour a,1, Seyed Mohammad Shokrolahi a,1, Ekaterina Bourova-Flin b,
Samira Derakhshan c, Zahra Shahsavari a, Abbas Karimi d,
Hassan Mir Mohammad Sadeghi e, Afsaneh Goudarzi a,*
a

Department of Clinical Biochemistry, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
CNRS UMR 5309/INSERM U1209/University Grenoble-Alpes/Institute for Advanced Biosciences, La Tronche, France
c
Oral and Maxillofacial Pathology Department, School of Dentistry, Tehran University of Medical Sciences, Tehran, Iran
d
Department of Oral and Maxillofacial Surgery, School of Dentistry, Tehran University of Medical Sciences, Tehran, Iran
e
Department of Oral and Maxillofacial Surgery, School of Dentistry, Shahid Beheshti University of Medical Sciences, Tehran, Iran
b

Abstract
Background: Altered acetyl CoA acetyltransferase 1 (ACAT1) expression has been reported in diverse cancers. However,
the expression of ACAT1 and its prognostic value in oral squamous cell carcinoma (OSCC) has remained unexplored.
Materials and methods: In this study, the expression of ACAT1 was analysed by immunohistochemistry (IHC) in 61
OSCC patients and compared between OSCC and adjacent pre-tumour tissue of 21 patients.
Results: The expression of ACAT1 in OSCC tumours is heterogeneous between patients. More speciﬁcally, 52.38% of
the patients show low expression of ACAT1 in both tumour and adjacent pre-tumour tissues, 9.52% of the patients show
high expression of ACAT1 in both tumour and adjacent pre-tumour, 19.05% of the patients have high expression of
ACAT1 in tumour tissue and low expression of ACAT1 in adjacent pre-tumour tissue and another 19.05% of the patients
have low expression of ACAT1 in tumour tissue and high expression of ACAT1 in adjacent pre-tumour tissue.
Conclusion: Comparison of ACAT1 expression, one of the key enzymes in the ketone body metabolic pathway, divided
OSCC patients into two groups: 1) similar expression and 2) different expression of ACAT1 in tumour and adjacent pretumour tissue. No signiﬁcant association between ACAT1 levels and overall survival was observed.
Keywords: ACAT1, OSCC, Metabolism

1. Introduction

O

ral squamous cell carcinoma (OSCC) is the
most common malignancy of oral cancer with
high mortality and 5-year survival is less than 50%
[1]. There is increasing evidence supporting the link
between altered metabolism and cancer [2,3]. The
metabolic dysregulation favours tumour growth and
identiﬁcation of changes in gene expression of enzymes involved in metabolic pathways could
expand the panel of cancer biomarkers as well as
therapeutic strategy [2,3]. Mitochondrial acetyl-CoA
acetyl transferase 1 (ACAT1) was previously recognized as a thiolase enzyme involved in the ketone

body metabolism, fatty acid beta oxidation and
isoleucine degradation pathway [4]. Interestingly,
several studies in diverse cancers revealed the
oncogenic function of ACAT1 recently, which occurs
through several mechanisms [5,6]. ACAT1 has been
discovered to have acetyltransferase activity, which
can acetylate several metabolic enzymes including
pyruvate dehydrogenase alpha (PDHA1) and pyruvate dehydrogenase phosphatase1 (PDP1) leading to
inhibition of PDHA1 and PDP1 and Warburg effect
[6]. In addition, a recent study by Fan et al. showed
that active tetrameric ACAT1 promotes tumour
growth while its disruption to monomeric form attenuates cancer cell proliferation [6]. The altered
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expression level of ACAT1 has been reported in
clear renal cell carcinoma, prostate cancer and
glioblastoma [5,7,8] and the understanding of the
molecular mechanisms underlying its oncogenic
role would still require further research. Additionally, since cancer cells require a high level of energy
to fulﬁll their rapid proliferation, the high level of
ketone body metabolic enzymes could help cancer
cells provide energy from both carbohydrates and
ketone bodies, therefore in cancer with a low level of
ketone body metabolic enzymes, carbohydrate restriction and ketogenic diet (KD) therapy could be
useful to inhibit tumour growth [7,9e14]. This study
aimed to investigate the expression level of ACAT1
between OSCC and the adjacent pre-tumour tissues
and its association with the survival of OSCC patients. Our study highlights differences in protein
expression levels of ACAT1 between OSCC patients, as well as between OSCC and adjacent pretumour tissues. These results suggest that only a few
OSCC cases with low expression of ACAT1 may
respond to KD therapy, although additional investigations of other enzymes related to the ketolysis would be required.

2. Methodology
2.1. Patients
Formalin-ﬁxed parafﬁn-embedded fresh human
OSCC and adjacent pre-tumour biopsy specimens
were selected to evaluate the expression of ACAT1
between OSCC and adjacent pre-tumour tissues.
These included 21 OSCC samples with their adjacent
pre-tumour tissues that were harvested at surgical
removal from hospitals (Bahman and Shariati, Tehran, Iran). All the OSCC patients were histopathologically diagnosed. Fresh tissues were immediately
ﬁxed in formalin for histological study. Adjacent pretumour tissues were harvested far from the margin of
tumours. Additionally, 40 OSCC parafﬁn embedded
tissues without adjacent pre-tumour tissues were
obtained from the archives of the Oral and Maxillofacial Department, Tehran Medical University. Altogether, an overall of 61 OSCC patients with parafﬁn
blocks were used to evaluate the association of
ACAT1 expression with survival probabilities. This
research project was approved by the Ethics Committee of Shahid Beheshti University of Medical Sciences (IR.SBMU.MSP.REC.1399.528).
2.2. Immunohistochemistry
The formalin-ﬁxed tissues obtained at surgical
removal were dehydrated and embedded in
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parafﬁn. Four-micrometer-thick parafﬁn sections
were prepared from OSCC and adjacent pretumour tissues, followed by deparafﬁnization in
xylene and rehydration in serial dilutions of ethanol.
The tissues were incubated in PBS 3% hydrogen
peroxide for 10 min. Next, the antigen retrieval was
performed using citrate buffer (pH ¼ 6) at 90  C for
15 min. The tissues were then incubated with the
ACAT1 primary antibody (Sigma HPA007569, 1/200)
for 1 h at RT, followed by three washes with PBS and
incubation with primary antibody ampliﬁer master
for 20 min, after washing with PBS, slides were
incubated with the secondary antibody for 30 min,
followed by washing in PBS. The signal was developed with DAB substrate solution, then counterstained with hematoxylin and dehydrated with
serial dilutions of alcohol and mounted.
2.3. Evaluation of immunohistochemical staining
The stained slides were observed using a light
microscope. For each slide, the intensity staining
score was applied as follows: 0 (negative), 1 (weak), 2
(moderate) and 3 (strong)) (Fig. 1). The score of
positively stained cells were deﬁned as follows:
0 (negative), 1 (1e25%), 2 (26e50%), 3 (51e75%) and
4 (76e100%). The total staining score of ACAT1 was
calculated in ﬁve randomly selected ﬁelds according
to the multiplication of the intensity score to the
score of positively stained cells. The high and low
expression of ACAT1 were considered based on the
total staining score of ACAT1 4 and < 4,
respectively.
2.4. Statistical analysis
The statistical analysis was performed using
Graphpad Prism software version 8. The ACAT1
percentage of positive cells and its total score were
compared between OSCC and adjacent pre-tumour
tissues using paired sample T test. Survival analysis
was performed using the KaplaneMeier method
and log-rank test with Python software and the
lifelines package. p-values < 0.05 were considered
statistically signiﬁcant.

3. Results
3.1. ACAT1 protein expression in OSCC and
adjacent pre-tumour tissues
The results from IHC performed on 61 OSCC
tissues using ACAT1 antibody showed that ACAT1
is variably expressed among OSCC tumours, with
high ACAT1 protein expression in 23 of 61 patients
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Fig. 1. Images of OSCC tissue samples immunostained with ACAT1 antibody showing the intensity scores from 0 to 3. IHC assay was
performed on parafﬁn-embedded sections of OSCC tissues using anti-ACAT1. The scores of signal intensities were assigned to ACAT1 as: negative
(0), weak [1], moderate [2] and strong [3] using a light microscope. Original magniﬁcation, 400; Scale bar ¼ 0.07 mm.

(37.7%) and low ACAT1 protein expression in 38 of
61 patients (62.3%). We then evaluated the ACAT1
expression in adjacent pre-tumour tissues and
looked for possible differences with OSCC tumour
tissue. To this end, we took advantage of 21 samples
for which both OSCC tumour and adjacent pretumour tissues were available. Variable ACAT1
protein expression was observed in pre-tumour
tissues, similar to OSCC tissues. Indeed, out of the
21 patients, high ACAT1 protein expression was
found in the pre-tumour tissue of 6 patients (29%)

and low ACAT1 protein expression in 15 patients
(71%). We then wanted to evaluate whether the
percentages of ACAT1 positively stained cells and
ACAT1 total score staining were similar or different
between tumour and their adjacent pre-tumour
matched tissues in our 21 patients. We performed a
paired sample T test and found a higher percentage
of ACAT1 positive cells in tumour tissues compared
to adjacent normal mucosa tissues (p-value ¼ 0.045)
whereas no signiﬁcant difference was observed between the total scores of tumour and adjacent pre-
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Fig. 2. Comparison of ACAT1 scores between OSCC and adjacent pre-tumour tissues. (A) The percentage score of tumour and adjacent pretumour tissues (B) Similarly, the ACAT1 total score of the tumour and adjacent pre-tumour tissues. (C and D) The results of paired sample t-test
comparing percentage and total score of ACAT1 between OSCC and adjacent pre-tumour tissues: *p-value <0.05.

tumour tissues (p-value ¼ 0.596) (Fig. 2). Additionally, the comparison of ACAT1 protein expression
according to the high and low level of ACAT1 total
score staining identiﬁed four groups of patients,
which include i/OSCClow/Normallow (11 out of 21
patients (52.38%)), ii/OSCClow/Normalhigh (4 of 21
patients (19.05%)), and iii/OSCChigh/Normallow (4 of
21 patients (19.05%)) and iv/OSCChigh/Normalhigh (2
of 21 patients (9.52%)) (Fig. 3) (Table S1).
3.2. ACAT1 protein expression and patient survival
We then investigated the association of ACAT1
expression according to the percentage of positively
ACAT1 stained cells, the score of percentage and
ACAT1's total staining score with the survival of
OSCC patients. KaplaneMeier analysis revealed no
signiﬁcant difference in overall survival between
stratiﬁed groups according to high and low levels of
ACAT1 (Fig. 4A, B and C).

4. Discussion
OSCC is the most common subtype of oral cancer.
Overall, cancer is a disease with mitochondrial

metabolism alterations which seems to beneﬁt from
dietary therapeutic approaches. The association of
enzymes responsible for catalyzing ketone bodies
with the progression of cancers, including prostate
and kidney, has been recently reported [5,8]. Among
these enzymes, ACAT1 has been shown as the most
interesting and promising candidate and its role
with respect to OSCC has yet to be identiﬁed.
Several studies have shown that cancer cells rely on
aerobic glycolysis and that carbohydrate restriction
decreases the supply of blood glucose level to cancer cells while enhancing the utilization of fatty
acids and ketone bodies in normal cells [12,14,15]. In
some cancer patients, the altered expression of
certain ketone body metabolic enzymes prevent the
tumour cells from obtaining energy from the
breakdown of ketone bodies, suggesting that ketogenic diet therapy and carbohydrate restriction
could selectively starve and kill cancer cells but not
normal cells [12,16]. It is of note that KD therapy in
combination with other therapeutic strategies, such
as chemotherapy and radiotherapy, could achieve
satisfactory results, whereas the positive effects of
KD therapy alone are still controversial [16,17]. In
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Fig. 3. Differential expression of ACAT1 in OSCC and adjacent pre-tumour tissues. Representative IHC results of 4 OSCC cases illustrate low
and high ACAT1 expression in OSCC and adjacent pre-tumour tissues. The four observed pattern of ACAT1 expression including OSCClow/Normallow, OSCChigh/Normallow, OSCClow/Normalhigh and OSCChigh/Normalhigh are shown from top to the bottom of panel. Scale bar: 0.07 mm.

the current study, we investigated the ACAT1 protein expression by IHC in a series of 61 OSCC patients and compared the results between OSCC and
adjacent pre-tumour tissues. Additionally, the potential of ACAT1 as a prognostic biomarker was
evaluated. A decreased ACAT1 expression was
observed in high grade and stages of clear cell renal
cell carcinoma, and ACAT1 expression was

signiﬁcantly reduced in clear cell renal cell carcinoma compared to adjacent normal kidney tissue
[8]. In contrast, an elevated expression of ACAT1
was reported in prostate cancer tissues compared to
the adjacent benign tissues, and high levels of
ACAT1 expression were observed in high grade and
advanced prostate cancer [5]. In our study on OSCC,
different expression levels of ACAT1 (low and high
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Fig. 4. Kaplan-Meier curves for overall survival analysis according to ACAT1 expression in OSCC patients. The stratiﬁcation of patients
according to the percentage of positively stained cells with ACAT1 antibody (A), the score of ACAT1 positively stained cells (B) and the total score of
ACAT1 (C) showed no signiﬁcant association with the survival of OSCC patients. *: p-value <0.05.

expression) were observed among 61 OSCC patients, observed low ACAT1 protein expression in 38
patients (62.3%), suggesting altered mitochondrial
metabolism in these OSCC. These variable expression levels of ACAT1 in OSCC tumours could be
explained by several hypotheses. First, since ACAT1
is an enzyme located in mitochondria, differences in
the number of mitochondria or deﬁcient mitochondria in some OSCC tumours could potentially affect
ACAT1 expression. Second, since OSCC tumours
are heterogeneous with different metabolic

switches, it is possible that tumours with high levels
of ACAT1 could generate ATP from both fat and
carbohydrates, whereas tumours with low levels of
ACAT1 would have to rely mostly on glycolysis and
therefore may not respond to KD therapy and carbohydrate restriction. Additionally, the ACAT1
expression in cancerous tissues compared to adjacent pre-tumour tissues did not follow any speciﬁc
trends in all the patients. This analysis was performed on a subset of 61 patients, which enabled us
to stratify them into four groups, including

OSCClow/Normallow,
OSCClow/Normalhigh,
high
low
OSCC
/Normal
and OSCChigh/Normalhigh. In
2016, Fan and colleagues reported an upregulated
ACAT1 activity despite comparable gene and protein expression in human leukaemia cells, head and
neck cancer and lung cancer cells, compared to their
corresponding normal cells [6], suggesting that an
altered ACAT1 activity could occur without any
differences in ACAT1 protein expression (OSCClow/
Normallow and OSCChigh/Normalhigh).
Since the expression levels of ACAT1, one of the
key enzymes in the ketone body metabolic pathway,
are variable between OSCC patients, a high-fat lowcarbohydrate diet (ketogenic), which increases the
amount of blood ketone bodies, would probably not
be able to disrupt the metabolism and therefore
would not increase the death of oral squamous
cancer cells in all OSCC tumours. These results
suggest that ACAT1 staining could help stratify
patients into different groups with respect to their
potential response to a ketogenic diet, although this
statement would still need to be strengthened by
analysing other ketolytic enzymes.
In conclusion, our measurements of ACAT1 protein expression did not show any clear common
trend regarding the relative expression levels of this
enzyme between OSCC and adjacent pre-tumour
tissues. Further studies would be required to elaborate on the reason behind these variations of
ACAT1 expression among OSCC patients. The main
limitation of this study was the evaluation of other
ketolytic enzymes including 3-hydroxybutyrate dehydrogenase 1(BDH1), 3-hydroxybutyrate dehydrogenase 2 (BDH2) and succinyl CoA: 3-oxoacid
CoA transferase 1 (OXCT1) in the tumour and pretumour tissues of the OSCC patients. To conclude
on the clinical application of this study, OSCC patients with observed low ACAT1 expression in their
tumour compared to the pre-tumour tissue may
respond better to ketogenic diet therapy, although
further investigations of BDH1, BDH2 and OXCT1
related to the ketolysis would be required.
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Appendix
Table S1
No

Age

Sex

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21

47
56
76
62
52
61
79
83
53
33
60
74
69
57
38
79
47
64
54
60
64

F
M
M
M
M
M
F
F
M
M
M
M
F
F
F
F
F
F
M
M
F

ACAT1
OSCC

PT

High
Low
High
Low
Low
Low
High
Low
Low
High
Low
Low
Low
High
Low
Low
Low
Low
Low
High
Low

Low
High
Low
Low
Low
Low
Low
Low
Low
High
Low
Low
High
High
Low
Low
Low
High
High
Low
Low
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